The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative obreast cancer (TNBC)
Authors: Awada, A., Hickish, T. et al.
Journal: CANCER RESEARCH
Volume: 73
eISSN: 1538-7445
ISSN: 0008-5472
DOI: 10.1158/0008-5472.SABCS13-P2-16-23
Source: Web of Science (Lite)